Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 5, 2015, Pages 525-530

  Simon, J ^a   Hawes, E ^b,c   Deyo, Z ^b   Bryant Shilliday, B ^d  

^a Robert C Byrd Center for Pharmacy Education   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

ambulatory care; anticoagulants; apixaban; dabigatran; factor Xa; rivaroxaban

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; APIXABAN; BILIRUBIN; CREATININE; DABIGATRAN; HEMOGLOBIN; RIVAROXABAN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; EMBOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HUMAN; INAPPROPRIATE PRESCRIBING; INCIDENCE; KIDNEY FUNCTION; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; OUTPATIENT DEPARTMENT; PRESCRIPTION; RETROSPECTIVE STUDY; TELEMEDICINE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 84941003169     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12296     Document Type: Article

References (17)

1. Guyatt GH, Akl EA, Crowther M, et al,. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141 (2 Suppl): 7S-47S.
2. Furie KL, Goldstein LB, Albers GW, et al,. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2012; 43: 3442-3453.
3. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 2013.
4. Food and Drug Administration. FDA Drug Safety Communication: Special Storage and Handling Requirements must be followed for Pradaxa (dabigatran etexilate mesylate) Capsules. Available at: http://www.fda.gov/drugs/drugsafety/ucm248746.htm (accessed 23 June 2014).
5. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) package insert. Gurabo, PR: Janssen Ortho, LLC, 2014.
6. Bristol-Myers Squibb Company. Eliquis (apixaban) package insert. Princeton, NJ: Bristol-Myers Squibb Company, 2014.
7. Heidbuchel H, Verhamme P, Alings M, et al,. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013; 15: 625-651.
8. Lopes RD, Alexander JH, Al-Khatib SM, et al,. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J, 2010; 159: 331-339.
9. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J, 2010; 159: 340.e1-347.e1.
10. World Health Organization. Adherence to long-term therapies: evidence for action, 2003.
11. Sackett DL, Snow JC,. The magnitude of adherence and nonadherence. In:, Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: Johns Hopkins University Press, 11-22, 1979.
12. Morisky DE, Ang A, Krousel-Wood M, et al,. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich), 2008; 10: 348-354.
13. Eikelboom JW, Wallentin L, Connolly SJ, et al,. Risk of bleeding With 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation, 2011; 123: 2363-2372.
14. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2012; 60: 616-631.
15. Ernst ME, Brandt KB,. Evaluation of 4 years of clinical pharmacist anticoagulation case management in a rural, private physician office. J Am Pharm Assoc (2003), 2003; 43: 630-636.
16. Verret L, Couturier J, Rozon A, et al,. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy, 2012; 32: 871-879.
17. Witt DM, Humphries TL,. A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care. J Thromb Thrombolysis, 2003; 15: 113-118.